(ICLR) ICON - Overview
Clinical Trials, Laboratory Services, Consulting, Commercialization
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 36.8% |
| Relative Tail Risk | -14.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.03 |
| Alpha | -25.03 |
| Character TTM | |
|---|---|
| Beta | 0.982 |
| Beta Downside | 1.074 |
| Drawdowns 3y | |
|---|---|
| Max DD | 63.43% |
| CAGR/Max DD | -0.12 |
Description: ICLR ICON January 03, 2026
ICON PLC (NASDAQ: ICLR) is a global contract research organization headquartered in Dublin that offers end-to-end outsourced services for drug and device development. Its portfolio spans strategic program design, Phase I-IV clinical trial execution, post-approval support, data analytics, decentralized and hybrid trial models, and a suite of laboratory services-including biomarker, vaccine, and GMP testing. ICON serves pharma, biotech, medical-device firms as well as government and public-health agencies across Ireland, Europe, the United States and other international markets.
Key recent metrics: FY 2023 revenue reached $4.9 billion, up ~7 % YoY, driven by strong demand for decentralized trial capabilities and real-world evidence solutions; the CRO industry is projected to grow at a CAGR of 7-8 % through 2028, underpinned by rising R&D spend (global pharma R&D outlays surpassed $210 billion in 2023) and tighter timelines for vaccine and oncology pipelines. ICON’s operating margin improved to 11.5 % as it leveraged scale efficiencies and higher-value services such as adaptive trial design and cardiac safety platforms.
For a deeper, data-driven assessment of ICON’s valuation relative to peers, you may find the analytics on ValueRay worth exploring.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 599.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -1.11 > 1.0 |
| NWC/Revenue: 2.34% < 20% (prev 11.56%; Δ -9.22% < -1%) |
| CFO/TA 0.07 > 3% & CFO 1.18b > Net Income 599.5m |
| Net Debt (3.10b) to EBITDA (1.18b): 2.63 < 3 |
| Current Ratio: 1.06 > 1.5 & < 3 |
| Outstanding Shares: last quarter (78.1m) vs 12m ago -6.43% < -2% |
| Gross Margin: 26.85% > 18% (prev 0.30%; Δ 2655 % > 0.5%) |
| Asset Turnover: 48.06% > 50% (prev 48.26%; Δ -0.20% > 0%) |
| Interest Coverage Ratio: 3.96 > 6 (EBITDA TTM 1.18b / Interest Expense TTM 199.4m) |
Altman Z'' 1.17
| A: 0.01 (Total Current Assets 3.41b - Total Current Liabilities 3.22b) / Total Assets 16.51b |
| B: 0.14 (Retained Earnings 2.31b / Total Assets 16.51b) |
| C: 0.05 (EBIT TTM 790.0m / Avg Total Assets 16.86b) |
| D: 0.31 (Book Value of Equity 2.23b / Total Liabilities 7.17b) |
| Altman-Z'' Score: 1.17 = BB |
Beneish M -3.00
| DSRI: 0.98 (Receivables 2.80b/2.94b, Revenue 8.10b/8.31b) |
| GMI: 1.10 (GM 26.85% / 29.58%) |
| AQI: 1.02 (AQ_t 0.76 / AQ_t-1 0.75) |
| SGI: 0.98 (Revenue 8.10b / 8.31b) |
| TATA: -0.04 (NI 599.5m - CFO 1.18b) / TA 16.51b) |
| Beneish M-Score: -3.00 (Cap -4..+1) = A |
What is the price of ICLR shares?
Over the past week, the price has changed by +0.78%, over one month by +2.17%, over three months by +4.83% and over the past year by -7.85%.
Is ICLR a buy, sell or hold?
- StrongBuy: 11
- Buy: 0
- Hold: 6
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ICLR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 206.4 | 10.8% |
| Analysts Target Price | 206.4 | 10.8% |
| ValueRay Target Price | 191.4 | 2.7% |
ICLR Fundamental Data Overview January 29, 2026
P/E Forward = 13.7552
P/S = 1.8042
P/B = 1.5331
P/EG = 1.4624
Revenue TTM = 8.10b USD
EBIT TTM = 790.0m USD
EBITDA TTM = 1.18b USD
Long Term Debt = 2.88b USD (from longTermDebt, last quarter)
Short Term Debt = 567.9m USD (from shortTermDebt, last quarter)
Debt = 3.57b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.10b USD (from netDebt column, last quarter)
Enterprise Value = 17.72b USD (14.62b + Debt 3.57b - CCE 468.9m)
Interest Coverage Ratio = 3.96 (Ebit TTM 790.0m / Interest Expense TTM 199.4m)
EV/FCF = 17.80x (Enterprise Value 17.72b / FCF TTM 995.8m)
FCF Yield = 5.62% (FCF TTM 995.8m / Enterprise Value 17.72b)
FCF Margin = 12.29% (FCF TTM 995.8m / Revenue TTM 8.10b)
Net Margin = 7.40% (Net Income TTM 599.5m / Revenue TTM 8.10b)
Gross Margin = 26.85% ((Revenue TTM 8.10b - Cost of Revenue TTM 5.93b) / Revenue TTM)
Gross Margin QoQ = 22.32% (prev 27.84%)
Tobins Q-Ratio = 1.07 (Enterprise Value 17.72b / Total Assets 16.51b)
Interest Expense / Debt = 1.41% (Interest Expense 50.2m / Debt 3.57b)
Taxrate = 8.94% (77.7m / 869.2m)
NOPAT = 719.3m (EBIT 790.0m * (1 - 8.94%))
Current Ratio = 1.06 (Total Current Assets 3.41b / Total Current Liabilities 3.22b)
Debt / Equity = 0.38 (Debt 3.57b / totalStockholderEquity, last quarter 9.33b)
Debt / EBITDA = 2.63 (Net Debt 3.10b / EBITDA 1.18b)
Debt / FCF = 3.12 (Net Debt 3.10b / FCF TTM 995.8m)
Total Stockholder Equity = 9.48b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.56% (Net Income 599.5m / Total Assets 16.51b)
RoE = 6.32% (Net Income TTM 599.5m / Total Stockholder Equity 9.48b)
RoCE = 6.39% (EBIT 790.0m / Capital Employed (Equity 9.48b + L.T.Debt 2.88b))
RoIC = 5.58% (NOPAT 719.3m / Invested Capital 12.90b)
WACC = 7.91% (E(14.62b)/V(18.19b) * Re(9.53%) + D(3.57b)/V(18.19b) * Rd(1.41%) * (1-Tc(0.09)))
Discount Rate = 9.53% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.07%
[DCF Debug] Terminal Value 76.79% ; FCFF base≈1.09b ; Y1≈979.9m ; Y5≈840.0m
Fair Price DCF = 160.4 (EV 15.35b - Net Debt 3.10b = Equity 12.25b / Shares 76.4m; r=7.91% [WACC]; 5y FCF grow -12.41% → 2.90% )
EPS Correlation: -31.43 | EPS CAGR: -45.23% | SUE: -4.0 | # QB: 0
Revenue Correlation: 72.89 | Revenue CAGR: 2.17% | SUE: 1.53 | # QB: 2
EPS next Quarter (2026-03-31): EPS=3.20 | Chg30d=-0.028 | Revisions Net=-4 | Analysts=13
EPS next Year (2026-12-31): EPS=13.23 | Chg30d=-0.159 | Revisions Net=-6 | Growth EPS=+1.2% | Growth Revenue=+0.0%